The new structure of the BJD includes a section dedicated to the assessment of clinical trials. The goal is to publish studies with the highest methodological quality and clinical relevance, performed in accordance with relevant ethical standards. Clinical trial authors are now aware of three mandatory aspects to submitting randomized controlled trials (RCTs) to the BJD. Firstly, the need for prospective registration of the RCT in a suitable trial registry; secondly, the reporting of all outcomes, avoiding 'salami slicing'; and thirdly, the completion of the CONSORT checklist at submission, to ensure clear, transparent reporting. Although the CONSORT guidelines were developed more than two decades ago, 1 their application remains patchy.